VBI-1

VBI-1 is an investigational cardiovascular support fluid developed by Vivacelle Bio. It is designed for the treatment of patients experiencing emergently life-threatening hypovolemia, such as severe blood loss (hemorrhagic shock) and potentially other critical conditions like reperfusion injury. VBI-1 represents a refined version of Vivacelle Bio’s earlier product, VBI-S. Its mechanism involves modulating nitric oxide bioavailability in the microcirculation—absorbing excess nitric oxide where it is overproduced and releasing it where levels are insufficient—thereby redistributing nitric oxide to promote survival rather than mortality. This approach aims to increase mean arterial pressure, reduce inflammation, and improve multi-organ function in critically ill patients[2][9]. As of early 2019, the FDA granted IND clearance for a phase IIa clinical trial evaluating its safety and efficacy after blood loss[4][9].